SRT2104

Phase 2Small molecule

GSK

SRT2104 is one of 130 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 2 Diabetes MellitusActive, not recruiting

AtrophyActive, not recruiting

PsoriasisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

AtrophyPhase 1

Active, not recruiting

PsoriasisPhase 2

Active, not recruiting

Ulcerative ColitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

676 competitors in Type 2 Diabetes Mellitus

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

20 2

Tanzeum

GSK

Preclinical

10 3

Insulin 320

Novo Nordisk

Preclinical

43 4

SRT2104

GSK

Phase 2

2 5

Adenocard

Astellas

Preclinical

1 6

NOVOLIN R

Novo Nordisk

Preclinical

1 7

Lantus

Sanofi

Preclinical

6 8

Lixisenatide

Sanofi

Preclinical

4 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 10

Glargine

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics3 trials

A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Normal Healthy Male Volunteers

Completed·—·Phase 1·NCT00933530·43 enrolled

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers

Completed· GSK logo

GSK·Phase 1·NCT00933062·10 enrolled

Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects

Completed·—·Phase 2·NCT00937326·227 enrolled

Type 2 Diabetes Mellitus2 trials

A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus

Completed· GSK logo

GSK·Phase 2·NCT01018017·86 enrolled

A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus

Completed·—·Phase 1·NCT01031108·38 enrolled

Ulcerative Colitis1 trial

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

Completed·—·Phase 1·NCT01453491·17 enrolled

Intravenous1 trial

A Clinical Study to Evaluate the Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension and Intravenous Microdose of 100 µg Carbon-14 Radio-labeled SRT2104 in Healthy Male Subjects

Completed·—·Phase 1·NCT00937872·9 enrolled

Prednisolone1 trial

Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy Volunteers

Completed· GSK logo

GSK·Phase 1·NCT00920660·20 enrolled

4 more indications

Inflammation1 trial

Effect of SRT2104 on Endotoxin-induced Inflammation

Completed· GSK logo

GSK·Phase 1·NCT01014117·41 enrolled

Atrophy1 trial

A Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human Volunteers

Withdrawn· GSK logo

GSK·Phase 1·NCT01039909

Elderly1 trial

A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days

Completed· GSK logo

GSK·Phase 1·NCT00964340·24 enrolled

Psoriasis1 trial

Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis

Completed·—·Phase 2·NCT01154101·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 12 trial records for SRT2104. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SRT2104 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SRT2104. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

SRT2104

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics3 trials

Type 2 Diabetes Mellitus2 trials

Ulcerative Colitis1 trial

Intravenous1 trial

Prednisolone1 trial

Inflammation1 trial

Atrophy1 trial

Elderly1 trial

Psoriasis1 trial

References

Drug Info

Quick Facts

Related News